BACKGROUND AND OBJECTIVES: Intravenous immunoglobulin (IVIG) is used in a range of immunodeficiency states that require a broad spectrum of protective antibodies to a range of common pathogens. A comparison of the antigen-specific antibody profile of preparations of an IVIG (Vigam) derived from US and UK sourced plasma was performed, and these preparations were also compared with three other IVIG products from different manufacturers. MATERIALS AND METHODS: Antibodies against a range of bacterial and viral pathogens were measured by immunoassay. RESULTS: Similar profiles were found for Vigam made from UK and US source plasma and also for the other three IVIGs tested, but some specific differences were observed. CONCLUSIONS: IVIG preparations have a similar therapeutic spectrum of antibodies when prepared from plasma sourced either from the UK or the US.
BACKGROUND AND OBJECTIVES: Intravenous immunoglobulin (IVIG) is used in a range of immunodeficiency states that require a broad spectrum of protective antibodies to a range of common pathogens. A comparison of the antigen-specific antibody profile of preparations of an IVIG (Vigam) derived from US and UK sourced plasma was performed, and these preparations were also compared with three other IVIG products from different manufacturers. MATERIALS AND METHODS: Antibodies against a range of bacterial and viral pathogens were measured by immunoassay. RESULTS: Similar profiles were found for Vigam made from UK and US source plasma and also for the other three IVIGs tested, but some specific differences were observed. CONCLUSIONS: IVIG preparations have a similar therapeutic spectrum of antibodies when prepared from plasma sourced either from the UK or the US.
Authors: M Ballow; L Notarangelo; B Grimbacher; C Cunningham-Rundles; M Stein; M Helbert; B Gathmann; G Kindle; A K Knight; H D Ochs; K Sullivan; J L Franco Journal: Clin Exp Immunol Date: 2009-12 Impact factor: 4.330
Authors: Malgorzata G Mikolajczyk; Nelydia F Concepcion; Theresa Wang; Douglas Frazier; Basil Golding; Carl E Frasch; Dorothy E Scott Journal: Clin Diagn Lab Immunol Date: 2004-11
Authors: J El-Bietar; A Nelson; G Wallace; C Dandoy; S Jodele; K C Myers; A Teusink; A Lane; S M Davies; L Danziger-Isakov Journal: Bone Marrow Transplant Date: 2016-05-16 Impact factor: 5.483